Patients must have measurable disease that is avid for phosphonate compounds as demonstrated by a positive technetium TC-99m (Tc-99m) bone scan; not all lesions must be positive on bone scan
Clinical T2-T4c, any N, M0 invasive ER+ (Allred score of 6-8) and HER2 negative (0 or 1+ by immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH] negative for amplification) breast cancer, by American Joint Committee on Cancer (AJCC) 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node\r\n* Note: patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or ductal carcinoma in situ (DCIS) in the contralateral breast the patient are eligible
PIK3CA WILD TYPE COHORT (closed 03/17/2016): Clinical T2-T4c, any N, M0 invasive ER+ (Allred score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node\r\n* Note: patients with invasive ER+ (Allred score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible
ENDOCRINE RESISTANT COHORT: Clinical T2-T4c at diagnosis or screening, any N, M0 invasive ER+ (Allred score at least 3 or > 1% ER positivity) and HER2 negative (0 or 1+ by IHC or FISH negative or equivocal) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node\r\n* Note: patients with invasive breast cancer that is ER positive (pos), HER2 negative (neg) or equivocal or DCIS in the contralateral breast are eligible; multi-focal diseases are not excluded; the dominant lesion will be followed per protocol
The primary tumor can be clinical stage T2 or T3, if clinically node negative according to AJCC 7th Edition. If the regional lymph nodes are cN1 and cytologically or histologically positive or cN2-N3 with or without a biopsy, the primary breast tumor can be clinically T1c, T2, or T3.
American Joint Committee on Cancer (AJCC) 7th edition clinical stages T1c to T2c
Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging
Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III).
Clinical stage T1c-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging prior to neoadjuvant chemotherapy
Clinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging prior to neoadjuvant chemotherapy, with residual invasive breast cancer after neoadjuvant therapy; if the patient has invasive cancer in the contralateral breast, she is not eligible for this study
Clinical stage T1c-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging prior to neoadjuvant chemotherapy, with residual invasive breast cancer after neoadjuvant therapy; if the patient has invasive cancer in the contralateral breast, she is not eligible for this study
Clinical T2-T4c, any N, M0 invasive estrogen receptor positive (ER+) (Allred Score of 6-8) and human epidermal growth factor receptor 2 negative (HER2-) (0 or 1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] negative for amplification) breast cancer by American Joint Committee on Cancer (AJCC) 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node; patients with T1c tumors are eligible if they are considered candidates for neoadjuvant endocrine therapy
Clinical stages T2c or greater (AJCC Criteria 6th Ed.)
Clinical stages T1c-T3c (American Joint Committee on Cancer [AJCC] sixth edition)
Either clinical or pathological Stage I (T1c), II, or III according to AJCC 7th edition
Patients who are diagnosed with clinical stage T1a -T2c prostate cancer
T1c, N1-N2
Clinical T2-T4c, any N, M0 invasive ER+ (Allred score of 6-8) and HER2 negative (0 or 1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] negative for amplification) breast cancer, by American Joint Committee on Cancer (AJCC) 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node; \r\n* Note: if the patient has invasive or ductal carcinoma in situ (DCIS) in the contralateral breast the patient is not eligible for this study
Patient has T1c-T3, any N, M0, operable breast cancer
Early stage breast cancer (T1c-3, cN0-3, cM0)
Clinical stage T2c or less
Prostate cancer clinical stage T1c
Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed
All of the following staging criteria (according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:\r\n* By pathologic evaluation, primary tumor must be pT1-3\r\n* By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b\r\n* If pN0, pathological tumor must be >= 3.0 cm
Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition
Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) 7th edition and have had negative surgical margins
Stage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and metastasis (TNM) classification system
Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition staging criteria
Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).
Participants must have histologically confirmed stage IIIA or IIIB non-squamous non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC] 7th edition); patients with a clinical stage of IIIB are allowed only if they are thought to be a candidate for concurrent chemoradiation
Clinical stages T1a-T2a N0 M0 (AJCC Criteria 7th Ed.). Staging must be done by treating investigator.
Participants must have histologically confirmed stage IV non-small cell lung cancer (NSCLC) (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act [CLIA]-approved laboratory
Participants must have histologically confirmed stage IV NSCLC (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act (CLIA)-approved laboratory
Patients with non-metastatic breast cancer are eligible; this includes American Joint Committee on Cancer (AJCC) 7th edition left- or right-sided breast cancer clinical or pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis; for patients that receive neoadjuvant chemotherapy, AJCC 7th edition left- or right-sided breast cancer pathologic stage yp 0, I, II, III are eligible
Histologically or cytologically-confirmed recurrent or resistant (progression within 6 months following the last administered platinum based therapy or progression after subsequent therapy in previously relapsed subjects), stage III-IV epithelial ovarian, fallopian tube or peritoneal cancer subjects (according to American Joint Committee on Cancer/Union for International Cancer Control TNM and International Federation of Gynecology and Obstetrics Staging System, 7th edition) whose disease has progressed following adjuvant therapy or therapy for metastatic disease.
Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer [AJCC] 7th edition) squamous NSCLC.
Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer (AJCC) staging, 7th edition\r\n* Staging workup must include: brain imaging (CT head or magnetic resonance imaging [MRI] brain) and PET/CT\r\n* Pleural effusions must have cytology to rule out malignant involvement unless too small to undergo thoracentesis per radiology
Patients must have stage III, IVa or IVb disease as determined by imaging studies and complete head and neck exam; staging evaluation should be in accordance with the American Joint Committee on Cancer Staging Manual, 7th edition
Histologically or cytologically proven Stage IIb-IV melanoma (at diagnosis or at the time of recurrence) rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration; patients with treated brain metastases may be eligible if they meet the criteria. Small radiologic or clinical findings of an indeterminate nature will not be a basis for exclusion, and brain metastases will not be a basis for exclusion.\r\n* Staging of cutaneous melanoma will be based on the 7th edition American Joint Committee on Cancer (AJCC) staging system. Staging of mucosal melanomas will be based on the following system modified from the cutaneous melanoma staging system: 2.01- 4 mm primary with ulceration or > 4 mm primary = stage IIb, lymph node metastases = stage III, distant metastases = stage IV.
Pathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of the following stages (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition):\r\n* Stage IIIA or IIIB\r\n* Stage II NSCLC with medical contraindication to curative surgical resection\r\n* Stage IV disease with solitary brain metastasis that has been treated radically (eg: with surgical resection or stereotactic radiosurgery) and thoracic disease that would be classified as stage II-III
Pathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC] staging, 7th edition) within 4 weeks of registration; the patient should have histologically or cytologically confirmed N2 disease
AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.
Must meet stage II - III group criteria per AJCC Staging manual 7th edition.
Phase I and expansion cohort: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with clinical stage: IV (see American Joint Committee on Cancer [AJCC] staging criteria, 7th edition) or stage IIB-IIIC (expansion cohort only)
Phase II: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with the following clinical stage: IIB, IIIA, IIIB, or IIIC (see AJCC staging criteria, 7th edition); the tumor must be human epidermal growth factor receptor 2 (Her2)/neu negative (by DAKO HercepTest, fluorescence based in situ hybridization [FISH], or other approved assay)
Pathologic stages T2-T3b, N0-Nx-N1, M0-1 as staged by the pathology report (American Joint Committee on Cancer [AJCC] criteria 8th edition [Ed.])
Patients must have a clinical T stage documented by the treating urologist/medical oncologist within 90 days prior to treatment start using the seventh (7th) edition American Joint Committee on Cancer (AJCC) staging system, recorded as the urologist’s/medical oncologist’s best clinical assessment of extent of local disease by digital rectal examination and available imaging studies such as transrectal ultrasound, computed tomography (CT) scan, and/or MRI
Subjects with histologically confirmed advanced, progressive, well-differentiated nonfunctional NET of the pancreas, lung or gastrointestinal (GI) tract per the 7th International Association for the Study of Lung Cancer classification (IASLC) or the American Joint Committee on Cancer (AJCC) staging handbook, 7th edition
Stage IV (according to the American Joint Committee on Cancer [AJCC] 8th edition).
Clinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging
Patients who have stage III-IV disease without distant metastases (M0) of 1) oral cavity, 2) larynx, 3) hypopharynx 4) oropharynx (human papillomavirus [HPV] negative [neg]) using American Joint Committee on Cancer (AJCC) 8th edition
Patients who have oropharyngeal cancer that is HPV positive, stage II-III disease without distant metastases (M0) using AJCC 8th edition
Unicentric American Joint Committee on Cancer (AJCC) 7th edition T1N0M0 tumor measuring no greater than 2.0 cm in longest dimension on initial imaging with either breast magnetic resonance imaging (MRI) and/or mammogram
Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition proposed staging criteria
Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization [WHO] type 2a and 2b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration
Clinical stage T1-2, N0-1, or small volume N2b (American Joint Committee on Cancer [AJCC], 7th ed.), with no distant metastases, based on routine staging workup.
Clinical stage T1-T2, N1-N2b or T3, N1-N2b (American Joint Committee on Cancer [AJCC] 7th edition) with no distant metastases based on the following diagnostic workup
Suspected or histologically/cytologically confirmed oropharyngeal squamous cell carcinoma (OPSCC), stage II, III, or IVA (according to the American Joint Committee on Cancer [AJCC] 7th edition), or patients with loco-regional recurrence from an OPSCC primary, if time of recurrence is at least 6 months after completion of initial curative intent treatment (surgery or radiotherapy +/- chemotherapy or cetuximab). Patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study. If squamous cell histology is not confirmed, patients will be discontinued from the study
Clinical stage I (breast tumor >= 1.0 cm in diameter), stage II or stage III breast cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th Edition, 2010); multifocal disease is allowed if confined to 1 breast, as long as one tumor is at least 1 cm and meets all of the other inclusion criteria
Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) N2-N3 nodal disease or T3-T4 primary tumor
Patient must have pathologically-confirmed and previously untreated:\r\n* Non-small cell lung cancer, stage IIIA (T1-3 N2 M0) OR\r\n* Localized esophageal cancer, >= T2, or N+, and M0 according to the American Joint Committee on Cancer (AJCC) 7th edition staging
Stage IA-IIIA NSCLC by 8th edition American Joint Committee on Cancer (AJCC) staging (that is deemed to be surgically resectable by a board certified thoracic surgeon
Stage IIIB or IV NSCLC as per 8th edition AJCC staging
All subjects must be either recurrent or stage IV American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with confirmed pathology in order to be eligible
Clinical stage I-IVB (American Joint Committee on Cancer [AJCC], 7th edition); stages I-II glottic cancer are excluded
Clinical or pathologic stage Stage III-IVb per the American Joint Committee on Cancer (AJCC), 7th edition.
Stage I or II; T1N1 and T2N1 stage III presentations per AJCC 7th edition
Have pathologically confirmed diagnosis of advanced NSCLC (stage IIIB or stage IV, as defined by the American Joint Committee on Cancer staging system-TNM 7th edition, 2010)
Patients must have histologically or cytologically confirmed stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancer
Patient's disease state must be American Joint Committee on Cancer (AJCC) 7th edition stage I-III
Histologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the 7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and the American Joint Committee on Cancer.
Stage IIIB-IV, locally advanced or metastatic disease according to the 7 th edition of the AJCC lung cancer TNM classification system
Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
Clinical American Joint Committee on Cancer (AJCC) 7th edition stage T2N1M0, T3N0M0 or T3N1M0 based on physical examination, CT scan chest/abdomen/pelvis, and pelvic magnetic resonance imaging (MRI) or endorectal ultrasound
Documented history of clinical stage IV (any T, any N, M1a/b) disease as per American Joint Committee on Cancer (AJCC) staging system 7th edition
Patients must be classified post-operatively as Stage IB (? 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
Clinical American Joint Committee on Cancer (AJCC) stage (7th edition) IIA-IIIB NSCLC (T1-4N0-3M0)
Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
Clinical stage a =< T1-2a (American Joint Committee on Cancer [AJCC] 7th edition)
Pathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
Clinical stage T1-2b (American Joint Committee on Cancer [AJCC] 7th edition) and PSA < 20 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy
Histologically confirmed stage III colorectal cancer as determined by American Joint Committee on Cancer (AJCC) 7th edition
Patients must have documented, clinically measurable 7th edition American Joint Committee on Cancer (AJCC) stage IIIB/C (bulky nodal and/or in transit disease) or stage IV (distant metastatic) melanoma; patients with brain metastases that have been appropriately treated with surgical resection and/or radiation are eligible for inclusion if they meet the performance status and life expectancy criteria; patients who are BRAF V600E mutation positive need to have failed, refused, or be ineligible for at least 2 lines of therapy (vemurafenib plus one other regimen)
Clinical stage T1b-T2b, N0-Nx, M0-Mx (American Joint Committee on Cancer [AJCC] 6th Edition)\r\n* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, computed tomography [CT], and/or magnetic resonance imaging [MRI])\r\n* M-stage determined by physical exam, CT or MRI; bone scan not required unless clinical findings suggest possible osseous metastases
Patients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC
Patient with histologically or cytologically confirmed non-resectable or metastatic stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanoma
Clinical stage II or stage III (by American Joint Committee on Cancer [AJCC] 7th edition) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapy
If both of the following conditions are present, the patient is ineligible:\r\n* < 10 pack-year smoking history\r\n* p16-positive carcinoma of the oropharynx or unknown primary that are T0-3, N0-2b (AJCC 7th Edition)\r\n** Note: in the event that a registered patient has a p16-positive result on central review with the tumor and nodal stage T0-3, N0-2b (AJCC 7th Edition), then the site will be notified that the patient is ineligible
Participants must have presented at initial diagnosis with extensive-stage disease (defined as stage IV [T any, N any, M1a/b] per National Comprehensive Cancer Network [NCCN] guidelines version 1.2015, American Joint committee on Cancer [AJCC] staging manual, seventh [7th] edition, 2010)
Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC); patients should have stage IV disease (American Joint Committee on Cancer [AJCC] 7th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field; measurable or evaluable disease is required
Oropharyngeal primaries have to be human papillomavirus (HPV) p16 negative, unless by American Joint Committee on Cancer (AJCC) 7th edition staging they are cT4a, cT4b, cN2 and/or cN3 tumors
Patients with stage IV (locally advanced or metastatic) disease; the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition will be used for staging; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be used for measurable disease
Patients must have histologically or cytologically confirmed:\r\n* Extensive stage small cell lung cancer (SCLC) or \r\n* Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or \r\n* Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy \r\n** NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy
Patient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage 2, 3, 4a, or 4b (by American Joint Committee on Cancer [AJCC] 7th edition [ed.])
Patients must be clinical American Joint Committee on Cancer (AJCC) stage IIIA or IIIB (AJCC, 7th ed.) with non-operable disease; non-operable disease will be determined by a multi-disciplinary treatment team, involving evaluation by at least 1 thoracic surgeon within 8 weeks prior to registration; Note: For patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and a medical oncologist, or pulmonologist
Pathologically proven diagnosis of stage IIIA (T1-T3) (American Joint Committee on Cancer [AJCC] Staging, 7th edition) with a single primary lung parenchymal lesion and ipsilateral positive mediastinal nodes within 12 weeks of registration; note: the primary tumor does not require tissue diagnosis; documentation of non-small cell carcinoma may originate from the mediastinal node biopsy or aspiration
Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer (NSCLC)
Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by the American Joint Committee on Cancer (AJCC) 7th Edition staging criteria
Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer [AJCC] 7th edition T1-4N0-1M1)
Patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage II or III non small cell lung cancer, (according to AJCC staging, 6th edition), or recurrent non small cell lung cancer; histologic confirmation of cancer will be required by biopsy or cytology within 9 months of study entry
Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.
Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible
Pathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC 7th edition (R12-4710)
Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
Pathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)
There must be histologic confirmation of high risk, adenocarcinoma of the colon defined as AJCC 7th Edition Stage IIIB or IIIC.
Pathologically confirmed (histology or cytology) clinical Stage II, III, or IVA squamous cell cancer of the oral cavity (excluding lip). Subjects must be staged using AJCC Cancer Staging Manual Edition 7.0 (appendices 1 and 2).
Stage IIIC colorectal cancer (T4a, N2a, M0) or (T3-4a, N2b, M0), or (T4b, N1- N2, M0) (per AJCC 7th ed).
Have stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition).
Stage IB (with a primary tumor >= 4cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer [AJCC] 7th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
Participant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic platinum based chemotherapy.
Stage II or III esophageal carcinoma according to the American Joint Committee on Cancer (AJCC) 7th edition staging
Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) T1-T4 nodal stage N2 or N3 or a T3 or T4 primary tumor with any nodal stage
Clinical American Joint Committee on Cancer (AJCC) stage II-III (AJCC, 7th ed.) with plans to be treated with concurrent chemoradiotherapy\r\n* Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax\r\n* Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade =< 1
American Joint Committee on Cancer (AJCC) (7th edition) stage IIb, III, or IV patients planned for resection of the primary tumor \r\n* > 5 cm in greatest dimension\r\n* Intermediate or high-grade \r\n* Superficial or deep
COHORT A: History or presence of regional pelvic lymph nodes (as per American Joint Committee on Cancer [AJCC] Cancer Staging [7th edition]) will be considered a metastatic site if greater than 1.5 cm in shortest dimension
Any clinical T4 tumor as defined by tumor-node-metastasis classification in UICC/AJCC 7th edition, including inflammatory breast cancer
Clinical stage T1-2, N1-2c (American Joint Committee on Cancer [AJCC], seventh [7th] edition [ed.]) without evidence of distant metastasis based on fludeoxyglucose (FDG) PET/CT\r\n* Patients who have squamous cell carcinoma of the neck of unknown primary, and thus, are T0, are allowed with excision biopsy of a lymph node (or core biopsy) and consent from the principal investigator (PI) or coorperative (co)-PIs (Dr. Nancy Lee, Dr. Eric Sherman, or Dr. Nadeem Riaz)
With histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] 7th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinum
PART A: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the American Joint Committee on Cancer [AJCC] staging manual)
PART B: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the AJCC staging manual)
Suspected or histologically/cytologically confirmed head and neck squamous cell carcinoma (HNSCC) of the oral cavity, stage III, IVA or IVB (according to the American Joint Committee on Cancer [AJCC] 7th edition); patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study; if squamous cell histology is not confirmed, patients will be discontinued from the study
Stage IV disease by AJCC criteria (7th edition).
Stage II or III disease by the American Joint Committee on Cancer (AJCC) 7th edition
STEP 1 ENROLLMENT: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th Edition stage IV NSCLC
STEP 2 ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLC
Biopsy-proven invasive adenocarcinoma of the rectum, stage T3-4 and/or node-positive (American Joint Committee on Cancer [AJCC] stage II or III) per AJCC staging manual, 7th edition; patients with M1a rectal cancer (“metastasis confined to one organ or site [e.g., liver, lung, ovary, non regional node]\), stage IVA disease per the AJCC staging manual, 7th edition, are also eligible; for the purpose of this study, a tumor is located in the “rectum” when its distal edge is located =< 12cm from the anal verge; the distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferred
Histological diagnosis:\r\n* Histologically proven diagnosis of testicular seminoma\r\n** Histologically confirmed seminomatous germ cell tumor of the testis categorized as either \classical\ or \anaplastic”\r\n* Stage I disease\r\n** Any pT N0 M0 S0-3 (American Joint Committee on Cancer [AJCC], 7th Ed.)\r\n* Stage IIA or IIB disease\r\n** Any pT N1 M0 S0-3 (AJCC, 7th Ed.)\r\n** Any pT N2 M0 S0-3 (AJCC, 7th Ed.)\r\n** (At the discretion of the principal investigators, bulky stage IIB may be excluded from the study, according to National Comprehensive Cancer Center Guidelines)
Stage IV disease according to the 7th Edition of the American Joint Committee on Cancer staging system
Histologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewing’s, osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer (AJCC) (6th Edition) Stage III or T2a Stage II or Stage IV treatment naive patients planned for resection of the primary tumor, with resectable metastatic disease
Patients with American Joint Committee on Cancer (6th edition, 2002) stage IV cancer with distant metastases
The patient must have clinical stage T1-4, N0-3, M0-1, stage II-IVC carcinoma as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual; patients with T1N0M0 will be ineligible; patients with metastatic disease with a limited metastatic burden are eligible if obtaining local control is determined by their treating oncologist to be an important therapeutic goal
Patients with FDG-avid and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
For Phase II: Histological diagnosis of BRAF V600E/K melanoma, unresectable stage III or stage IV, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2011; must have measurable disease, and no prior systemic treatment for locally advanced or metastatic melanoma; previous local therapy is allowed; previous systemic treatment for any stage III disease that was subsequently rendered NED (no evidence of disease) by surgery is allowed except for ipilimumab and BRAF inhibitors; patients with resectable disease who do not want surgery for any reason are also allowed; measurable disease is defined as least one lesion that can be accurately measured in two dimensions with both diameters >= 1.0 cm; for computed tomography (CT)/magnetic resonance imaging (MRI) evaluations, an effective slice thickness is required of less than or equal to 5 mm; for slice thickness greater than 5 mm, both diameters must be greater than or equal to 2.0 cm at baseline
Patients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC) – locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural or pericardial effusion or pleural implants) OR recurrence after primary surgery or radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th edition [Ed])
Histologically-confirmed NSCLC Stage IV disease (according to the seventh edition of the lung cancer staging system)
Resected, histologically proven, cutaneous melanoma determined to be Stage IIb, IIc, or III; according to the American Joint Commission of Cancer Staging, 7th edition
All patients must be either Stage IIIb/c or Stage IV according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible. Please refer to the AJCC Cancer Staging Manual, 7th edition for a description of tumor, lymph node, metastasis and staging.
Subjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)5;
Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)
Histologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2009
Patient who have AJCC 8th edition Prognostic Stage Group II
Patients must have histologically or cytologically confirmed stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer [AJCC] 7th edition criteria) and be at sufficient risk for tumor recurrence; staging studies to exclude metastatic disease are not required in asymptomatic patients; however, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancer
Diagnosis of RCC that is defined as metastatic by standard criteria (American Joint Committee on Cancer [AJCC] 7th edition, 2010)
Enrolled in 7th or 8th grade
Histologically confirmed stage IV gastrointestinal (GI) cancer (American Joint Committee on Cancer [AJCC] 7th edition) currently sensitive to oxaliplatin containing chemotherapy regimen
Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical stage I or IIa, according to the 7th edition staging system of the American Joint Commission on Cancer for lung cancer (T1 or T2a, N0 or N1, M0)
Stage T1-4bN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* CT chest/abdomen with contrast\r\n* MRI pelvis with contrast\r\n* PET/CT of the whole-body or skull base to mid-thigh
Subjects with AJCC 7th edition stage TxN0 and M1 disease
Subjects with AJCC 7th edition stage TxN0, T4b, and M1 disease
Patients must have pathologically confirmed diagnosis of unilateral ductal carcinoma in situ with no evidence of microinvasive or invasive disease obtained by core needle biopsy within 4 months of registration; if the core biopsy describes “suspicion of microinvasion”, patients remain eligible; patients diagnosed by surgical excision are not eligible; patients with synchronous bilateral disease (i.e.,\r\nsynchronous DCIS or invasive cancer) are not eligible\r\n* Patients will be staged prior to registration according to the clinical staging criteria adapted from the American Joint Committee on Cancer (AJCC) Cancer Staging Data Forms of the AJCC Cancer Staging Manual, 7th Edition, 2009; Note: for consistency purposes, AJCC 7th Edition will continue to be used throughout the entire study enrollment period
Patients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook, seventh (7th) edition
Patient must have stage IIIA non-small cell lung cancer (T1-3N2) per American Joint Committee on Cancer (AJCC) 7th edition and must be considered to be surgically resectable
Eligible patients must have appropriate staging studies identifying them as specific subsets of American Joint Committee on Cancer (AJCC) 7th edition stage I or II based on only one of the following combinations of tumor, nodes, metastatic (TNM) staging:\r\n* T1a-b, N0, M0\r\n* T2a, N0, M0\r\n* T3 (invading the chest wall, < 5 cm in diameter) N0 M0
Patient must have clinical American Joint Committee on Cancer, 6th edition stage II or III breast cancer and be considered a candidate for curative mastectomy
American Joint Committee on Cancer (AJCC) 7th edition (ed.) stage cN0 or cN1 subsequently staged after surgery as stage pIB (N1mic), pIIA, pIIB, pIIIA, pIIIB, or N3a (10 or more axillary nodes) only: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery; note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollment
Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system
Histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system
Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), or next generation sequencing (NGS) via a Clinical Laboratory Improvement Act (CLIA)-certified local diagnostic test (LDT); OR
Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC (American Joint Committee on Cancer version 8)
Stage II/III disease as per American Joint Committee on Cancer (AJCC) staging 7.0\r\n* Baseline imaging with standard of care fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) scan and endoscopic ultrasound within 28 days prior to registration
American Joint Committee on Cancer (AJCC) (2009) stage IV melanoma, or stage III melanoma not curable by surgery and which is progressing; patients must have at least 1 target lesion measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Subjects with stage IV non-small cell lung cancer as defined by American Joint Committee on Cancer (AJCC).
Patients must have American Joint Committee on Cancer (AJCC) (2010) clinical stage T3-4, N0-1, M0 disease
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (8th edition) staging criteria:\r\n* AJCC stage IV (Tany, Nany, M1a(1), M1b(1), M1c(1) or M1d(1))\r\n* AJCC stage IIIC (at least N2b) or IIID with unresectable nodal/locoregional involvement
Diagnosis of advanced/unresectable melanoma (American Joint Committee on Cancer [AJCC] v.8 stage 3C/D/4)
Final American Joint Committee on Cancer (AJCC) version 7.0 stage 0-IIB (pathologic stage Tis, T1-T3, all must be N0 and M0 status)
History of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor.
Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.
Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] version 7.0 Staging manual) NSCLC
Metastatic (American Joint Committee on Cancer [AJCC] stage IV) RCC
Disease eligibility and stage\r\n* Histologically confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or renal carcinoma\r\n* Previously treated or previously untreated stage IV melanoma, stage IV lung cancer, and metastatic renal cancer by American Joint Committee on Cancer (AJCC) staging criteria\r\n* Presence of a lesion that is suitable for hypofractionated radiotherapy
Did not achieve pathological complete response (pCR) to any chemotherapy that was given with the intention to induce best response prior surgery. pCR is defined as the current American Joint Committee on Cancer (AJCC) breast cancer staging.
Presumed American Joint Committee on Cancer (AJCC) tumor stage I or II
Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] staging manual) NSCLC
American Joint Committee on Cancer (AJCC) stage 3 or 4 histologically proven NSCLC not amenable to curative therapy
Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7) non-small cell lung cancer
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria:\r\n* AJCC stage IV (T any, N any, M1a, b, or c)\r\n* AJCC stage IIIB or IIIC with unresectable nodal/locoregional involvement
American Joint Committee on Cancer (AJCC) clinical stage T2-T3 N0M0
Appropriate staging studies identifying as American Joint Committee on Cancer (AJCC) stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
History of another invasive cancer within 5 years with the exceptions of nonmelanoma skin cancers and American Joint Committee on Cancer (AJCC) stage 0 or 1 cancers that have a remote probability of recurrence in the opinion of the investigator
Diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) TNM stages:\r\n* Tx or T1-4 and\r\n* N1b, or N2b, or N2c, or N3 and \r\n* M0
Stage IV cancer by American Joint Committee on Cancer (AJCC) staging criteria (except for pancreatic cancer cohort)
American Joint Committee on Cancer (AJCC) T1 or T2; N0 or N1microscopic (mic); stage IA-IIA breast cancer
Stage IV (American Joint Committee on Cancer [AJCC]) breast cancer patients who have failed at least one conventional therapy for metastatic disease
Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tail
Have a history of surgically resected and pathologically proved American Joint Committee on Cancer (AJCC) stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas
Has a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced disease
Clinical stages IIA –IIIC (American Joint Committee on Cancer [AJCC] 2009)
Patients must have American Joint Committee on Cancer (AJCC) stage IIIC unresected or IV disease
Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)
Participants who have been diagnosed with clinical or pathologic stage IB to stage IIIA adenocarcinoma of the breast (any subtype) who have undergone, and recovered from primary therapy (any combination of surgery, radiation, and/or chemotherapy and/or trastuzumab used to treat newly diagnosed disease), with their last dose/treatment (of any single or combination treatment) being between 45 days and 6 months (180 days) prior to enrollment; staging will be based on the Seventh Edition American Joint Committee on Cancer (AJCC) staging system; (systemic staging with computed tomography [CT] or positron emission tomography [PET] scans is not required by AJCC and is not required nor exclusionary for this trial)
Pathologically (histologically) proven diagnosis of primary carcinoma of the bladder (transitional cell cancer) within 8 weeks of registration; operable patients whose tumors are primary carcinomas of the bladder and exhibit histologic evidence of muscularis propria invasion and are American Joint Committee on Cancer (AJCC) clinical stages T2-T4a, Nx or N0, M0
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 E or K mutation determined by pyrosequencing assay or Food and Drug Administration (FDA)-approved equivalent test, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria: \r\n* AJCC stage IV (Tany, Nany, M1a, b, or c) \r\n* AJCC stage III B or C with unresectable nodal/locoregional involvement
Unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.
Has locally advanced/metastatic disease, i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer (AJCC) or have recurrent disease.
Has locally advanced/metastatic disease (i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer) or has recurrent disease.
Male or female patients with metastatic, histologically- or cytologically-confirmed unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) of squamous histology (Staging per American Joint Committee on Cancer [AJCC], Edition 7). Mixed histology adenosquamous NSCLC will also be permitted.
Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastatic
Staging MRI must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c;
Pre- or post-menopausal women with stage II-III breast cancer (American Joint Committee on Cancer [AJCC] 2002)
Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.
Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system
Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
Staging studies must identify patient as American Joint Committee on Cancer (AJCC) stage I or II based on only 1 of the following combinations of primary tumor, regional lymph nodes, and distant metastases (TNM) staging:\r\n* T1, N0, M0\r\n* T2 (=< 7 cm), N0, M0\r\n* T3 (=< 7 cm), N0, M0
Stage T1-2N1-2c/T3-4N0-2c disease, as defined by American Joint Committee on Cancer (AJCC) criteria
Eligible patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage T1 (a, b, or c) or T2 (a, b, or c) adenocarcinoma of the prostate gland; the patient should not have direct evidence of regional or distant metastases after appropriate staging studies; histologic confirmation of cancer will be required by biopsy performed within 180 days of registration
Subjects with recurrent or refractory, metastatic disease (N1 or M1) fulfilling any of the following combinations of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging version 2010 and Fuhrman nuclear grading
Stage Tis, T1, or T2 laryngeal squamous cancer as defined by American Joint Commission on Cancer (AJCC) 2007 staging system
Cancer should be staged via American Joint Committee on Cancer (AJCC) as stage II, III, IVa, or IVb
Clinical stage T1N0M0 (by American Joint Committee on Cancer [AJCC] 2010 criteria)\r\n* Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be =< 1 cm
Has a histologically-confirmed, unresectable or metastatic (Stage IV American Joint Committee on Cancer [AJCC seventh edition]) colorectal cancer (CRC)
American Joint Committee on Cancer (AJCC [2009]) stage IIIC cutaneous melanoma rendered free of disease by surgical resection no greater than 90 days prior study enrollment; patients with unknown primaries will be eligible for this trial; patients with a history of resected stage I or II cutaneous melanoma who subsequently have their first disease recurrence meeting the criteria for stage IIIC disease will also be eligible for this trial
Patients with recurrent, inoperable stage III, IV, M1a, b or c melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (American Joint Committee on Cancer [AJCC]); previously treated with any form of therapy (including chemotherapy, radiation therapy, immunotherapy or surgery) for either metastatic, relapsed, or primary melanoma are eligible for this trial, provided the previous treatment was completed > 30 days prior to enrollment
Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
Patients with American Joint Committee on Cancer (AJCC) seventh edition stage 4 metastatic non-small cell lung carcinoma
Has extensive-stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer (AJCC), Seventh Edition
Has previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee of Cancer (AJCC) staging criteria for breast cancer as assessed by the investigator based on radiological and/or clinical assessment:
Patient must be American Joint Committee on Cancer (AJCC) stage III (T3N0, T1-2N1) or stage IVa (T1-4N2-3M0, T4N0-1 M0) or stage IVb (unresectable disease) and be either unresectable or borderline resectable
Histological diagnosis of unresectable American Joint Committee on Cancer (AJCC) stage III or stage IV, v-raf murine sarcoma viral oncogene homolog B1 V600E/K mutation (BRAFV600E/K) mutant melanoma by a Clinical Laboratory Improvement Assessment (CLIA) approved test
Histological or cytological diagnosis of squamous cell carcinoma (SCC) of head and neck with American Joint Committee on Cancer (AJCC) Stage III, IVA or IVB and not amenable to surgical resection or locoregional radiation therapy with curative intent.
Stage IIIB disease not amenable to surgery or curative intent. Note: It is permissible to use either AJCC Version 6.0 or the AJCC Version 7.0 staging system. For sites that use AJCC Version 7.0, T4M0 patients with other ipsilateral nodules and N0-N2 are still eligible.
Pts undergoing extrapleural pneumonectomy without PDT for MPM or stage IV (M1A) NSCLC (after American Joint Committee on Cancer [AJCC] staging change 2010) or stage IIIB (before staging change) with malignant pleural effusion treated at Ohio State University (OSU) from 2005-2012
Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).
Patients must have histologically or cytologically confirmed metastatic melanoma; this includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inoperable stage III; this also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases
Histologically or cytologically documented, locally advanced or metastatic (i.e., stage IIIB not eligible for definitive chemoradiotherapy, stage IV, or recurrent) NSCLC (per the American Joint Committee [AJCC] staging system)
Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
Cancer should be staged via American Joint Committee on Cancer (AJCC) as IIIA or IIIB
Cancer should be staged via American Joint Committee on Cancer (AJCC) as IIA, IIB, or III (T3 or T4, any N, M0)
Patients must have histologically or cytologically confirmed metastatic melanoma (includes American Joint Committee on Cancer [AJCC] stage IV or advanced/inoperable stage III; also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases)
Histologically confirmed cutaneous melanoma with unresectable stage III disease, or stage IV disease by American Joint Committee on Cancer (AJCC) criteria
Patients must have metastatic malignant melanoma or metastatic renal cell cancer (American Joint Committee on Cancer [AJCC] stage IV [M1] or equivalent disease); metastatic renal cell cancer patients must either have refused treatment with, have been unable to tolerate or have experienced progressive disease after treatment with sorafenib or sunitinib, and temsirolimus
Advanced (stage IIIB or IV) lung adenocarcinoma diagnosed by biopsy of the primary or metastatic site (American Joint Committee on Cancer 7.0)
Prostate cancer, with organ-localized disease with very low risk of disease recurrence, as indicated by stage pT2, N0, M0 lesions (if American Joint Committee on Cancer [AJCC] staging is not available in medical records, the investigators will infer the staging based on extensive review of the pathology report), combined Gleason score of 7 (3+4) or less, and preoperative PSA < 10 ng/ml
History of another invasive cancer within 5 years of randomization with the exceptions of (a) non-melanoma skin cancers and (b) American Joint Committee on Cancer (AJCC) stage 0 or 1 cancers that have a remote probability of recurrence, in the opinion of the treating physician, in consultation with the principal investigator
Stage 3 or 4 under the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (IUCC) staging system OR patients with stage 1 or 2 disease who will receive radiation equivalent to patients with stage 3 or 4 disease
Patients with American Joint Committee on Cancer (AJCC) stage II-IV head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with concurrent chemoradiotherapy (CCRT) and who are capable of understanding and adhering to the protocol requirements
Patients must have limited disease SCLC after clinical staging evaluation: clinical tumor, lymph nodes, metastasis (TNM) stages I-IIIB (i.e., confined to one hemithorax, but excluding T4 tumor based on malignant pleural effusion and N3 disease based on contralateral hilar or contralateral supraclavicular involvement) according to American Joint Committee on Cancer (AJCC) 1997 staging manual to be consistent with Radiation Therapy Oncology Group (RTOG) 0212
American Joint Committee on Cancer (AJCC) stage I to IV lung cancer requiring radiation therapy (3-dimensional [3D] conformal or stereotactic) or systemic therapy, with or without surgery
American Joint Committee on Cancer (AJCC) stage I, II, III or IV non-small-cell lung cancer as well as distant metastasis within the lung to be treated using radiotherapy will be eligible for this study
Patients who have undergone pathology review of their prostate biopsy at Emory University, Grady Memorial Hospital, Saint Joseph’s Hospital, and Atlanta VA Medical Center with American Joint Committee on Cancer (AJCC) clinical stage T1-T2 prostate cancer by physical exam.
American Joint Committee on Cancer (AJCC) stage 1, 2, 3 breast carcinoma
Has histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.
Histologically or cytologically confirmed stage IV (metastatic) NSCLC as defined by American Joint Committee on Cancer (AJCC); recurrent but not metastatic disease is allowed if deemed incurable
Histologically or cytologically confirmed stage III-IV (non-metastatic) SCCHN as defined by American Joint Committee on Cancer (AJCC); nasopharyngeal cancer patients will be excluded; note that in rare instances, a cancer may be clearly invasive on imaging, but pathology may not be definitive (e.g. in-situ carcinoma); in such cases, the patient will be eligible if the unanimous opinion of the institutional tumor board is that the situation is definitive for invasive SCCHN
